Next-Gen Blood-Clotting Treatment Gets FDA Approval
The drug, which would be used for patients with hemophilia A, was made and tested at Bayer HealthCare's Berkeley campus.
The San Francisco Business Times:
With FDA Approval, Berkeley's Got A Brand New Drug
A next-generation blood-clotting treatment — made and tested at Bayer HealthCare's Berkeley campus — won approval from the Food and Drug Administration for use by hemophilia A patients, the company said Thursday. FDA approval of Kovaltry, which last month scored European and Canadian regulatory approvals, is a next-step move by Bayer to protect and build on its longtime hemophilia A franchise. Kogenate FS for hemophilia A patients is the German company's second-best-selling product, and Bayer continues development of an experimental once-a-week treatment, called damoctocog. (Leuty, 3/16)